Patents by Inventor Kwang Woo Kim

Kwang Woo Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11236146
    Abstract: Disclosed is a stable pharmaceutical formulation, comprising a fusion protein in which the extracellular ligand-binding domain of a human p75 tumor necrosis factor receptor is fused to the Fc domain of human IgG and a succinate buffering agent, without comprising a stabilizer. The stable pharmaceutical formulation enables the long-term storage of the TNFR-Fc fusion protein formulation and can exhibit superior storage stability without the need for demanding storage conditions, and is a simple formulation because no stabilizer is comprised therein and is thus more economical than other stabilizer-comprising formulations.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: February 1, 2022
    Assignee: Celltrion Inc.
    Inventors: Joon Won Lee, Won Yong Han, Su Jung Kim, Jun Seok Oh, So Young Kim, Kwang Woo Kim, Yeon Kyeong Shin
  • Publication number: 20210347861
    Abstract: A stable liquid pharmaceutical preparation of an anti-influenza virus antibody and, more specifically, a stable liquid pharmaceutical preparation that comprises: (A) an anti-influenza virus antibody or a mixture of two or more different types of anti-influenza virus antibodies; (B) a surfactant; (C) a sugar or a sugar derivative; and (D) an amino acid. The stable liquid pharmaceutical preparation for an anti-influenza virus antibody disclosed herein has excellent storage stability at low temperature (5° C.), room temperature (25° C.), and high temperature (40° C.) and excellent long-term (12 months) storage stability, and may be administered intravenously, intramuscularly, transdermally, subcutaneously, intraperitoneally, topically, or in combinations thereof.
    Type: Application
    Filed: August 9, 2017
    Publication date: November 11, 2021
    Inventors: Joon Won Lee, Won Yong Han, Su Jung Kim, Jun Seok Oh, So Young Kim, Kwang Woo Kim, Yeon Kyeong Shin
  • Publication number: 20210315813
    Abstract: A stable liquid pharmaceutical formulation according to the present invention includes an antibody or antigen-binding fragment thereof, a surfactant, a sugar or a sugar derivative, a buffer, and a stabilizer. The stable liquid pharmaceutical formulation according to the present invention has low viscosity not only when antibody content is low but also when antibody content is high, and exhibits superior long-term storage stability based on superior stability observed under accelerated conditions and harsh conditions.
    Type: Application
    Filed: July 18, 2019
    Publication date: October 14, 2021
    Applicant: CELLTRION INC.
    Inventors: So Young Kim, Yeon Kyeong Shin, Hye Young Kang, Kwang Woo Kim, Jun Seok Oh, Su Jung Kim, Joon Won Lee, Won Yong Han, Jae Bin Lee, Ji Won Roh, Ji Min Kwak
  • Publication number: 20210205454
    Abstract: Disclosed is a stable liquid formulation, comprising an antibody or antigen-binding portion thereof, an acetate buffer, glycine, and a surfactant, wherein the stable liquid formulation does not comprise at least one of sugar, a sugar alcohol and a metal salt, and the stable liquid formulation is still stable even upon high antibody content, and is superior in osmolality and viscosity, and subcutaneous administration thereof is possible.
    Type: Application
    Filed: March 16, 2021
    Publication date: July 8, 2021
    Applicant: CELLTRION INC.
    Inventors: Joon Won LEE, Yeon Kyeong SHIN, Hye Young KANG, Kwang Woo KIM, So Young KIM, Su Jung KIM, Jun Seok OH, Won Yong HAN
  • Patent number: 10980881
    Abstract: Disclosed is a stable liquid formulation, comprising an antibody or antigen-binding portion thereof, an acetate buffer, glycine, and a surfactant, wherein the stable liquid formulation does not comprise at least one of sugar, a sugar alcohol and a metal salt, and the stable liquid formulation is still stable even upon high antibody content, and is superior in osmolality and viscosity, and subcutaneous administration thereof is possible.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: April 20, 2021
    Assignee: CELLTRION INC.
    Inventors: Joon Won Lee, Yeon Kyeong Shin, Hye Young Kang, Kwang Woo Kim, So Young Kim, Su Jung Kim, Jun Seok Oh, Won Yong Han
  • Publication number: 20190343956
    Abstract: Disclosed is a stable liquid formulation, comprising an antibody or antigen-binding portion thereof, an acetate buffer, glycine, and a surfactant, wherein the stable liquid formulation does not comprise at least one of sugar, a sugar alcohol and a metal salt, and the stable liquid formulation is still stable even upon high antibody content, and is superior in osmolality and viscosity, and subcutaneous administration thereof is possible.
    Type: Application
    Filed: January 10, 2018
    Publication date: November 14, 2019
    Applicant: CELLTRION INC.
    Inventors: Joon Won LEE, Yeon Kyeong SHIN, Hye Young KANG, Kwang Woo KIM, So Young KIM, Su Jung KIM, Jun Seok OH, Won Yong HAN
  • Publication number: 20190248871
    Abstract: Disclosed is a stable pharmaceutical formulation, comprising a fusion protein in which the extracellular ligand-binding domain of a human p75 tumor necrosis factor receptor is fused to the Fc domain of human IgG and a succinate buffering agent, without comprising a stabilizer. The stable pharmaceutical formulation enables the long-term storage of the TNFR-Fc fusion protein formulation and can exhibit superior storage stability without the need for demanding storage conditions, and is a simple formulation because no stabilizer is comprised therein and is thus more economical than other stabilizer-comprising formulations.
    Type: Application
    Filed: October 26, 2017
    Publication date: August 15, 2019
    Inventors: Joon Won LEE, Won Yong HAN, Su Jung KIM, Jun Seok OH, So Young KIM, Kwang Woo KIM, Yeon Kyeong SHIN
  • Patent number: 9587280
    Abstract: One embodiment of the present invention provides a detection kit for detecting c-Met gene expression, wherein the detection kit includes a primer set which is specifically bound to the c-Met gene; and a cleavable probe which is specifically bound to the inside of a c-Met gene amplification product which is amplified by the primer set. Another embodiment of the present invention provides a method of measuring the c-Met gene expression by using the detection kit according to one embodiment of the present invention. The method according to one embodiment of the present invention is used to efficiently detect a low concentration of c-Met gene expression for cancer diagnosis and prognosis diagnosis.
    Type: Grant
    Filed: January 9, 2013
    Date of Patent: March 7, 2017
    Assignee: Samsung Life Public Welfare Foundation
    Inventors: Kwang Woo Kim, Jong Won Kim, Do Hyun Nam, Chang-Seok Ki
  • Patent number: 9512488
    Abstract: One embodiment of the present invention provides a detection kit for detecting a chronic myelogenous leukemia (CML) gene expression, wherein the detection kit includes a primer set which is specifically bound to the CML gene; and a cleavable probe which is specifically bound to the inside of a CML gene amplification product which is amplified by the primer set. Another embodiment of the present invention provides a method of measuring the CML gene expression by using the detection kit according to one embodiment of the present invention. The method according to one embodiment of the present invention is used to efficiently detect a low CML gene expression for CML diagnosis and prognosis diagnosis.
    Type: Grant
    Filed: January 9, 2013
    Date of Patent: December 6, 2016
    Assignee: Samsung Life Public Welfare Foundation
    Inventors: Kwang Woo Kim, Jong Won Kim, Do Hyun Nam, Chang-Seok Ki
  • Publication number: 20150247200
    Abstract: One embodiment of the present invention provides a detection kit for detecting c-Met gene expression, wherein the detection kit includes a primer set which is specifically bound to the c-Met gene; and a cleavable probe which is specifically bound to the inside of a c-Met gene amplification product which is amplified by the primer set. Another embodiment of the present invention provides a method of measuring the c-Met gene expression by using the detection kit according to one embodiment of the present invention. The method according to one embodiment of the present invention is used to efficiently detect a low concentration of c-Met gene expression for cancer diagnosis and prognosis diagnosis.
    Type: Application
    Filed: January 9, 2013
    Publication date: September 3, 2015
    Applicant: Samsung Life Public Welfare Foundation
    Inventors: Kwang Woo Kim, Jong Won Kim, Do Hyun Nam, Chang-Seok Ki
  • Publication number: 20150038360
    Abstract: One embodiment of the present invention provides a detection kit for detecting a chronic myelogenous leukemia (CML) gene expression, wherein the detection kit includes a primer set which is specifically bound to the CML gene; and a cleavable probe which is specifically bound to the inside of a CML gene amplification product which is amplified by the primer set. Another embodiment of the present invention provides a method of measuring the CML gene expression by using the detection kit according to one embodiment of the present invention. The method according to one embodiment of the present invention is used to efficiently detect a low CML gene expression for CML diagnosis and prognosis diagnosis.
    Type: Application
    Filed: January 9, 2013
    Publication date: February 5, 2015
    Inventors: Kwang Woo Kim, Jong Won Kim, Do Hyun Nam, Chang-Seok Ki
  • Publication number: 20120185302
    Abstract: The present invention relates to a method for operating a prepaid taxi service. The method for operating a prepaid taxi is performed by a prepaid taxi management server connected to a reserving user personal computer (PC), an Internet payment system, and a taxi driving system over an Internet-based network. The method includes (a) receiving an origin and a destination searched for and selected by a reserving passenger who desires to use a prepaid taxi, (b) searching for and providing an optimal route by searching for routes between the origin and the destination, and calculating a travel distance along the optimal route, (c) calculating a taxi fare based on the calculated travel distance, and (d) receiving payment of the taxi fare calculated at (c) in conjunction with the Internet payment system.
    Type: Application
    Filed: September 7, 2010
    Publication date: July 19, 2012
    Inventors: Dong Soo Kim, Kwang Woo Kim, Seung Hyun Kim, Hyung Soo Park, Seung Myun Sung, Nam Eok Lee, Jung Soo Choi